Navigation Links
Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)
Date:6/11/2009

patients who were given Caldolor reported a significant reduction in post-surgical pain intensity within the first 24 hours while also significantly reducing their morphine use. Clinical trials including critically ill and non-critically ill patients with fever showed a significant reduction in temperature as compared with those who received a placebo. No serious adverse events were directly attributed to Caldolor in any of these clinical studies.

"We are delighted to obtain FDA approval for the first and only intravenous treatment for pain and fever in the U.S. market," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet medical needs. We believe Caldolor represents a significant addition to our product portfolio and a substantial market opportunity."

Caldolor is the third drug in Cumberland's portfolio and the second for which Cumberland has completed development and secured FDA approval. The company will promote Caldolor in the United States through its expanded hospital sales force and will use alliances with marketing partners for sales outside of the United States. Caldolor is expected to be available in the U.S. later this year.

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patient
'/>"/>

SOURCE Cumberland Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
2. Cumberland Emerging Technologies and UT Research Foundation Sign License Agreement for New Technology
3. Cumberland Pharmaceuticals Appoints Lee Product Director
4. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
5. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
6. Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients
7. Jubilant to Work With Endo Pharmaceuticals on Drug Development
8. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
9. ADVENTRX Pharmaceuticals Announces Financing
10. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
11. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... RI (PRWEB) January 22, 2015 Protocol ... , The growing team of brand-neutral, independent consultants, Protocol ... Philip Rogers explained that over the years, his company ... , Moroso, Town of Plainfield, as well as others. ...
(Date:1/22/2015)... Boston, MA (PRWEB) January 22, 2015 ... systems, is pleased to announce an exciting product from a ... of motion analysis solutions over the past 15 years, with ... industries. Most recently, their 3D IMU system (inertial measurement unit), ...
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 23D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... Kits, Water ... Filters and Reusable Bottles, MONROVIA, Calif., Sept. 12 ... the minds of consumers who fear the impact of,bottled water on ... Testing has assembled a family of products on its website, http://www.discovertesting.com, ...
... New Jersey, September 12, Rosetta Genomics Ltd. ... of microRNA-based diagnostics and therapeutics, announced,today the ... present AACR,s,upcoming Molecular Diagnostics in Cancer Therapeutic ... Rosetta Genomics,unique microRNA-based technologies and current development ...
... BARCELONA, Spain, Sept. 12 Elekta is pleased ... planning and,performing Volumetric Intensity Modulated Arc Therapy (VMAT)*. ... featured in the Elekta booth at,this year,s European ... September 8-13, 2007. Performing VMAT with Elekta,enables helical- ...
Cached Biology Technology:Discover Testing Settles the Drinking Water Debate: Tap vs. Bottled 2Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference 2Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO 2Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO 3
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and ... the addition of the "Global Wearable Technologies ... Growth, Share, Overview, Trends and Forecast 2014-2020" ... Wearable Technologies are smart devices that can be ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... for even the most diligent dieters. But are weekends ... and Quinnipiac University in Hamden, Conn., found that weekend ... a University of Pittsburgh professor of marketing and associate ... School of Business, and his coauthor, Adwait Khare, Quinnipiac ...
... world meet in Copenhagen from December 7󈝾 for the United ... of Delaware are taking a leading role. A special day ... housed at UD, is being set aside during the negotiations ... Day, to be held Dec. 14, will highlight the direct ...
... additional brush strokes to the revolutionary new image now emerging ... cord. Their report, which suggests a key role for astrocytes ... online in ACS, Journal of Proteome Research , a ... point out that nearly everyone viewed astrocytes the most ...
Cached Biology News:Oceans day at International Climate Change Conference 2
Request Info...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
...
Request Info...
Biology Products: